![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png)
Mercola breaks it down quite well in this article.
Here's the latest (Aug 2011) study.
Excellent article here by Dr Schor, on Aspirin/Cox inhibitors for breast cancer prevention or prevention of recurrence:
http://www.naturalmedicinejournal.com/article_content.asp?edition=1§ion=2&article=271&utm_source=Natural+Medicine+Journal+List&utm_campaign=6379125056-December_2011_Issue11_28_2011&utm_medium=email
Pearl: Over-expression of COX-2 occurs in about 40% of invasive breast cancer cases and is more common in large tumors, positive lymph nodes, ductal histology, and tumors that are high histological grade or hormone receptor–negative. Thus it makes even more sense to attempt to affect COX activity in women whose cancers fit these criteria.
Here's the latest (Aug 2011) study.
Excellent article here by Dr Schor, on Aspirin/Cox inhibitors for breast cancer prevention or prevention of recurrence:
http://www.naturalmedicinejournal.com/article_content.asp?edition=1§ion=2&article=271&utm_source=Natural+Medicine+Journal+List&utm_campaign=6379125056-December_2011_Issue11_28_2011&utm_medium=email
Pearl: Over-expression of COX-2 occurs in about 40% of invasive breast cancer cases and is more common in large tumors, positive lymph nodes, ductal histology, and tumors that are high histological grade or hormone receptor–negative. Thus it makes even more sense to attempt to affect COX activity in women whose cancers fit these criteria.